Insulin refill adherence among type 2 diabetes mellitus patients attending public health clinics in Perlis, Malaysia

Poor adherence to diabetes medications, particularly insulin, is still a concern. This study aimed to assess insulin refill adherence among diabetes patients attending public health clinics in Perlis before and during the COVID-19 pandemic. The underlying factors associated with insulin refill adherence were also investigated. This cross-sectional study was conducted among type 2 diabetes mellitus patients with insulin therapy from five primary health clinics in Perlis. Simple random sampling method was used to select participants from the Pharmacy Information System (PhIS) database. Adherence to insulin refill was measured by medication possession ratio before and during the COVID-19 pandemic. A general linear model was used to identify factors associated with adherence to insulin refills. A total of 426 patients were included in this study. Patients in this study were mostly Malay (94.3%) and female (63.1%). The insulin refill adherence was significantly poorer during the COVID-19 pandemic (mean=59.24, SD=28.97) than before the pandemic (mean=68.31, SD=31.27) (p<0.001). Only total daily insulin dose (adjusted β = -0.129; p=0.012) and not having hypertension (adjusted β = -7.359; p=0.043) were significantly associated with insulin refill adherence. This study highlighted that overall insulin refill adherence among patients in public health clinics in Perlis was still low, especially during the COVID-19 pandemic. Special attention should be given to patients using high total daily insulin doses and having no hypertension to improve adherence

Stingless bee honey protects against lipopolysaccharide induced-chronic subclinical systemic inflammation and oxidative stress by modulating Nrf2, NF-κB and p38 MAPK

Background: Epidemiological and experimental studies have extensively indicated that chronic subclinical systemic inflammation (CSSI) and oxidative stress are risk factors for several chronic diseases, including cancer, arthritis, type 2 diabetes, and cardiovascular and neurodegenerative diseases. This study examined the protective effect of stingless bee honey (SBH) supplementation against lipopolysaccharide (LPS)-induced CSSI, pointing to the possible involvement of NF-κB, p38 MAPK and Nrf2 signaling. Methods: CSSI was induced in male Sprague Dawley rats by intraperitoneal injection of LPS three times per week for 28 days, and SBH (4.6 and 9.3 g/kg/day) was supplemented for 30 days. Results: LPS-induced rats showed significant leukocytosis, and elevated serum levels of CRP, TNF-α, IL-1β, IL-6, IL-8, MCP-1, malondialdehyde (MDA) and 8-hydroxy-2′-deoxyguanosine (8-OHdG), accompanied with diminished antioxidants. Treatment with SBH significantly ameliorated inflammatory markers, MDA and 8-OHdG, and enhanced antioxidants in LPS-induced rats. In addition, SBH decreased NF-κB p65 and p38 MAPK, and increased Nrf2 expression in the liver, kidney, heart and lung of LPS-induced rats. Furthermore, SBH prevented LPS-induced histological and functional alterations in the liver, kidney, heart and lung of rats. Conclusion: SBH has a substantial protective role against LPS-induced CSSI in rats mediated via amelioration of inflammation, oxidative stress and NF-κB, p38 MAPK and Nrf2 signaling